Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com


Molecular Profile FLT3 exon 14 ins
Therapy Decitabine + Sorafenib
Indication/Tumor Type acute myeloid leukemia
Response Type sensitive

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
FLT3 exon 14 ins acute myeloid leukemia sensitive Decitabine + Sorafenib Case Reports/Case Series Actionable In a clinical study, treatment with Nexavar (sorafenib) in combination with Dacogen (decitabine) was well tolerated and resulted in an overall response rate of 83% (5/6, 1 complete remission (CR) and 4 CR with incomplete count recovery) with a median overall survival of 155 days in patients with acute myeloid leukemia (AML) harboring a FLT3 internal tandem duplication (FLT3-ITD) mutation, and the combination synergistically inhibited growth of a FLT3-ITD positive AML cell line in culture (PMID: 26297284). 26297284
FLT3 exon 14 ins acute myeloid leukemia sensitive Decitabine + Sorafenib Guideline Actionable Nexavar (sorafenib) in combination with Dacogen (decitabine) is included in guidelines for patients with relapsed or refractory acute myeloid leukemia harboring a FLT3 internal tandem duplication (FLT3-ITD) mutation (NCCN.org). detail...
PubMed Id Reference Title Details
NCCN.org Full reference...
(26297284) Decitabine and Sorafenib Therapy in FLT-3 ITD-Mutant Acute Myeloid Leukemia. Full reference...